Enfermedades reumáticas y alergias; la dualidad del sistema inmunológico

Autores/as

  • Gabriela Athziri Sánchez-Zuno Instituto de Investigación de Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara. Jalisco, México. https://orcid.org/0000-0002-4390-8604
  • Edith Oregón-Romero Instituto de Investigación de Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara. Jalisco, México. https://orcid.org/0000-0001-6010-0837
  • Jorge Hernández-Bello Instituto de Investigación de Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara. Jalisco, México. https://orcid.org/0000-0001-8004-1811
  • Guillermo González-Estevez Instituto de Investigación de Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara. Jalisco, México. https://orcid.org/0000-0002-0244-6298
  • Rodrigo Vargas-Rosales Escuela de Estudios de Postgrado, Facultad de Ciencias Médicas , Universidad de San Carlos de Guatemala. Ciudad de Guatemala, Guatemala
  • José Francisco Muñoz-Valle Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

Palabras clave:

alergias, enfermedades reumáticas, autoinmunidad, hipersensibilidad, lupus eritematoso sistémico, síndrome de Sjogren, artritis reumatoide

Resumen

Las enfermedades reumáticas autoinmunes son trastornos multisistémicos que afectan principalmente las articulaciones y los músculos; algunos ejemplos de estas afecciones son la artritis reumatoide (AR), el lupus eritematoso sistémico (LES) y el síndrome de Sjögren (SS). En general, las enfermedades reumáticas autoinmunes tienen una alta prevalencia en todo el mundo y son altamente incapacitantes para quienes las padecen. Una de las principales limitaciones en la actualidad para el manejo de estas enfermedades es que su factor desencadenante  sigue siendo desconocido en la mayoría de los casos y el conocimiento de los factores asociados a su exacerbación es limitado. En esta revisión se explorará la posible relación de las alergias como desencadenante de enfermedades reumáticas autoinmunes. Así también, analizaremos los aspectos básico y generales de ambas enfermedades y el desarrollo de procesos alérgicos y reacciones de hipersensibilidad a los fármacos utilizados en el tratamiento de enfermedades reumáticas.

Citas

Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. The Lancet. 2013;382(9894):797-808. doi:10.1016/S0140-6736(13)61499-3

Classification and response criteria subcommittee of the american college of rheumatology committee on quality measures. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348-352. doi:10.1002/art.22003

Cardiel MH. Presente y futuro de las enfermedades reumáticas en Iberoamérica. ¿Estamos preparados para hacerles frente? Reumatol Clínica. 2011;7(5):279-280. doi:10.1016/j.reuma.2010.12.009

Gourley M, Miller FW. Mechanisms of Disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol. 2007;3(3):172-180. doi:10.1038/ncprheum0435

Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007;19(1):49-54. doi:10.1097/BOR.0b013e32801127c8

Bach J-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018;18(2):105-120. doi:10.1038/nri.2017.111

Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clin Exp Immunol. 2006;143(1):1-5. doi:10.1111/j.1365-2249.2005.02940.x

Shunsheng Han C. A specific hygiene hypothesis. Med Hypotheses. 2016;93:146-149. doi:10.1016/j.mehy.2016.05.029

Versini M, Jeandel P-Y, Bashi T, Bizzaro G, Blank M, Shoenfeld Y. Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications. BMC Med. 2015;13(1):81. doi:10.1186/s12916-015-0306-7

Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann Allergy Asthma Immunol. 2004;93(2):S45-S54. doi:10.1016/S1081-1206(10)61486-X

Pawankar R, Canonica GW, Holgate ST, Lockey RF. Libro Blanco sobre Alergia de la WAO. :26.

Lerner BA, Green PHR, Lebwohl B. Going Against the Grains: Gluten-Free Diets in Patients Without Celiac Disease—Worthwhile or Not? Dig Dis Sci. 2019;64(7):1740-1747. doi:10.1007/s10620-019-05663-x

Rocchi V, Puxeddu I, Cataldo G, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology. 2014;53(8):1527-1529. doi:10.1093/rheumatology/keu181

Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454. doi:10.1038/nature07204

Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218-230. doi:10.1038/nri2262

Renz H, Skevaki C. Early life microbial exposures and allergy risks: opportunities for prevention. Nat Rev Immunol. 2021;21(3):177-191. doi:10.1038/s41577-020-00420-y

Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol. 2016;16(12):751-765. doi:10.1038/nri.2016.111

Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005;5(4):271-283. doi:10.1038/nri1589

Simon D. Recent Advances in Clinical Allergy and Immunology. Int Arch Allergy Immunol. 2018;177(4):324-333. doi:10.1159/000494931

Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016;138(3):639-652. doi:10.1016/j.jaci.2016.06.003

Kaur BP, Secord E. Innate Immunity. Pediatr Clin North Am. 2019;66(5):905-911. doi:10.1016/j.pcl.2019.06.011

Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761-771. doi:10.1038/nri1934

Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019;16(3):225-235. doi:10.1038/s41423-019-0210-8

Karsh J, Chen Y, Lin M, Dales R. The Association between Allergy and Rheumatoid Arthritis in the Canadian Population. Eur J Epidemiol. 2005;20(9):783-787. doi:10.1007/s10654-005-0704-9

Scheurer S, Toda M, Vieths S. What makes an allergen? Clin Exp Allergy. 2015;45(7):1150-1161. doi:10.1111/cea.12571

Ramos PS. Population Genetics and Natural Selection in Rheumatic Disease. Rheum Dis Clin N Am. 2017;43(3):313-326. doi:10.1016/j.rdc.2017.04.001

Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primer. 2018;4:1-23. doi:10.1038/nrdp.2018.1

Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-730. doi:10.1038/nrrheum.2016.186

Yao Y, Ma J-F, Chang C, et al. Immunobiology of T Cells in Sjögren’s Syndrome. Clin Rev Allergy Immunol. 2021;60(1):111-131. doi:10.1007/s12016-020-08793-7

Rehan OM, Abdel H, Saleh K, Raffat HA, Abu-taleb NS. Osseous changes in the temporomandibular joint in rheumatoid arthritis : A cone-beam computed tomography study. Published online 2018:1-9.

Bugatti S, Vitolo B, Caporali R. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. BioMed Res Int. 2014;2014(Article ID 681678):14. doi:10.1155/2014/681678

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2328-2337. doi:10.1016/S0140-6736(17)31472-1

Pisetsky DS. The Immunopathogenesis and Immunopathology of Systemic Lupus Erythematosus. In: Schur PH, Massarotti EM, eds. Lupus Erythematosus. Springer New York; 2012:13-26. doi:10.1007/978-1-4614-1189-5_2

Beccastrini E, D’Elios MM, Emmi G, et al. Systemic Lupus Erythematosus: Immunopathogenesis and Novel Therapeutic Targets. Int J Immunopathol Pharmacol. 2013;26(3):585-596. doi:10.1177/039463201302600302

Rose T, Dörner T. Drivers of the immunopathogenesis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):321-333. doi:10.1016/j.berh.2017.09.007

Huang Y, Cheng Q, Jiang C, et al. The Immune Factors Involved in the Pathogenesis, Diagnosis, and Treatment of Sjogren’s Syndrome. Clin Dev Immunol. 2013;2013:1-6. doi:10.1155/2013/160491

Valenta R, Mittermann I, Werfel T, Garn H, Renz H. Linking allergy to autoimmune disease. Trends Immunol. 2009;30(3):109-116. doi:10.1016/j.it.2008.12.004

Cosme-Blanco W, Arroyo-Flores E, Ale H. Food Allergies. Pediatr Rev. 2020;41(8):403-415. doi:10.1542/pir.2019-0037

Lee LA, Burks AW. Food Allergies: Prevalence, Molecular Characterization, and Treatment/Prevention Strategies. Annu Rev Nutr. 2006;26(1):539-565. doi:10.1146/annurev.nutr.26.061505.111211

Sicherer SH, Sampson HA. Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141(1):41-58. doi:10.1016/j.jaci.2017.11.003

Karatay S, Erdem T, Kiziltunc A, et al. General or personal diet: the individualized model for diet challenges in patients with rheumatoid arthritis. Rheumatol Int. 2006;26(6):556-560. doi:10.1007/s00296-005-0018-y

Lidén M, Kristjánsson G, Valtysdottir S, Venge P, Hällgren R. Cow’s milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjögren’s syndrome. Clin Exp Allergy. 2008;38(6):929-935. doi:10.1111/j.1365-2222.2008.02983.x

Hvatum M. The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. Gut. 2006;55(9):1240-1247. doi:10.1136/gut.2005.076901

Radzikowska U, Rinaldi AO, Çelebi Sözener Z, et al. The Influence of Dietary Fatty Acids on Immune Responses. Nutrients. 2019;11(12):2990. doi:10.3390/nu11122990

Isasi C, Tejerina E, Morán LM. Sensibilidad al gluten no celíaca y enfermedades reumatológicas. Reumatol Clínica. 2016;12(1):4-10. doi:10.1016/j.reuma.2015.03.001

Kim-Lee C, Suresh L, Ambrus JL. Gastrointestinal disease in Sjogren’s syndrome: related to food hypersensitivities. SpringerPlus. 2015;4(1):766. doi:10.1186/s40064-015-1557-7

Chan BCL, Lam CWK, Tam L-S, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Front Immunol. 2019;10:364. doi:10.3389/fimmu.2019.00364

Murdaca G, Greco M, Tonacci A, et al. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. Int J Mol Sci. 2019;20(23):5856. doi:10.3390/ijms20235856

Takatori H, Makita S, Ito T, Matsuki A, Nakajima H. Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation. Front Immunol. 2018;9:2004. doi:10.3389/fimmu.2018.02004

Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in Autoimmunity and Inflammation. J Pharmacol Exp Ther. 2015;354(1):24-31. doi:10.1124/jpet.114.222505

Xu D, Jiang H-R, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci. 2008;105(31):10913-10918. doi:10.1073/pnas.0801898105

Mu R, Huang H-Q, Li Y-H, Li C, Ye H, Li Z-G. Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis. J Rheumatol. 2010;37(10):2006-2013. doi:10.3899/jrheum.100184

Verri WA, Souto FO, Vieira SM, et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis. 2010;69(9):1697-1703. doi:10.1136/ard.2009.122655

Hong Y-S, Moon S-J, Joo Y-B, et al. Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L) in Patients with Rheumatoid Arthritis. J Korean Med Sci. 2011;26(9):1132. doi:10.3346/jkms.2011.26.9.1132

Chen S, Chen B, Wen Z, Huang Z, Ye L. IL-33/ST2-mediated inflammation in macrophages is directly abrogated by IL-10 during rheumatoid arthritis. Oncotarget. 2017;8(20):32407-32418. doi:10.18632/oncotarget.16299

Wu J, Li Q, Deng J, Zhao J-J, Yu Q-H. Association between IL‑33 and other inflammatory factors in patients with rheumatoid arthritis and in fibroblast‑like synoviocytes in vitro. Exp Ther Med. 2020;21(2):161. doi:10.3892/etm.2020.9592

Yu S-L, Wong C-K, Tam L-S. The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. Expert Rev Clin Immunol. 2013;9(8):739-749. doi:10.1586/1744666X.2013.814428

Xu W, Liu Y, Ye D. Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population. Immunol Invest. 2016;45(7):575-583. doi:10.1080/08820139.2016.1193868

Guo J, Xiang Y, Peng Y-F, Huang H-T, Lan Y, Wei Y-S. The association of novel IL-33 polymorphisms with sIL-33 and risk of systemic lupus erythematosus. Mol Immunol. 2016;77:1-7. doi:10.1016/j.molimm.2016.07.001

Awada A, Nicaise C, Ena S, et al. Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren’s syndrome. Ann Rheum Dis. 2014;73(6):1259-1263. doi:10.1136/annrheumdis-2012-203187

Jung SM, Lee J, Baek SY, et al. The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association. J Rheumatol. 2015;42(2):264-271. doi:10.3899/jrheum.140234

Margiotta D, Navarini L, Vadacca M, Lo Vullo M, Pignataro F, Basta F. The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. Eur Rev Med Pharmacol Sci. 2016;(20):1295-1299.

Chiu Y-M, Chen D-Y. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207-228. doi:10.1080/1744666X.2019.1705785

Benjamin O, Bansal P, Goyal A. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls Publishing; 2021. Accessed November 9, 2021. https://www.ncbi.nlm.nih.gov/books/NBK507863/

Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019;40(6):470-473. doi:10.2500/aap.2019.40.4274

Smitten A, Choi H, Hochberg M, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387-393.

Jenks K, Stamp L, O’Donnell J, Savage R, Chapman P. Leflunomide-associated infections in rheumatoid arthritis. The Journal of Rheumatology. 2007;34(11):2201-2203.

Cildag S, Senturk T. Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases: JCR J Clin Rheumatol. 2017;23(2):77-79. doi:10.1097/RHU.0000000000000490

Rutkowski K, Wagner A, Rutkowski R. Immediate hypersensitivity reactions to steroids and steroid containing medications. Curr Opin Allergy Clin Immunol. 2020;20(4):362-366. doi:10.1097/ACI.0000000000000655

Vatti RR, Ali F, Teuber S, Chang C, Gershwin ME. Hypersensitivity Reactions to Corticosteroids. Clin Rev Allergy Immunol. 2014;47(1):26-37. doi:10.1007/s12016-013-8365-z

Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219-1232. doi:10.1111/all.12260

Publicado

2021-10-13

Número

Sección

Artículos de revisión